Alexandra Silveira, Ph.D.
About Alexandra Silveira, Ph.D.
Alexandra Silveira, Ph.D., is the Director of Scientific Communications at Alkermes with over a decade of experience in the pharmaceutical and biotechnology industry.
Company
Alexandra Silveira, Ph.D., is currently employed at Alkermes as the Director of Scientific Communications. Alkermes is a global biopharmaceutical company that develops innovative medicines in the fields of neuroscience and oncology. The company focuses on therapies for chronic and serious conditions such as addiction, schizophrenia, and multiple sclerosis.
Title
Alexandra Silveira, Ph.D., holds the title of Director of Scientific Communications at Alkermes. In this role, she leads strategic planning for scientific communications within the company, ensuring that the dissemination of scientific information is accurate, coherent, and targeted to the relevant audiences.
Education and Expertise
Alexandra Silveira earned a Bachelor of Science (B.S.) degree in Biology from Providence College. She then pursued a Doctor of Philosophy (Ph.D.) in Pathology from the University of Alabama at Birmingham. Additionally, she completed a Post-Doctoral Fellowship in Ophthalmology at Harvard Medical School and attended Women's Unlimited. Her expertise spans over a decade in the pharmaceutical and biotechnology industry, with a focus on strategic planning for scientific communications.
Professional Background
Before her current position at Alkermes, Alexandra Silveira served as the Associate Director of Scientific Communications at the same company from 2017 to 2019. Prior to that, she held various roles at Biogen, including Sr Manager of Scientific Communications, Manager of Medical Communications, and Sr Scientific Writer. At PAREXEL, she worked as a Scientific Specialist and Scientific Writer. Her professional journey has been marked by increasing responsibilities and depth in scientific communications.
Therapeutic Area Expertise
Alexandra Silveira has substantial therapeutic area and research experience, including oncology, diabetes, molecular biology, cancer, genetics, lipidology/cardiovascular disease, biologics, multiple sclerosis, neurology, ophthalmology, and psychiatry. This extensive background allows her to contribute effectively to cross-functional initiatives and strategic discussions within the industry.